Cargando…

Second‐line lurbinectedin as a new treatment option for small‐cell lung cancer: Preliminary results in real‐clinical practice

INTRODUCTION: Few strategies exist for treatment of patients with small‐cell lung cancer (SCLC) extended‐stage after failure of first‐line platinum‐based chemotherapy. Lurbinectedin is a novel RNA‐polymerase‐II inhibitor investigated as a second‐line therapy for SCLC. However, its efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toublanc, Anne‐Claire, Guecamburu, Marina, Veillon, Rémi, Rosellini, Pietro, Girodet, Pierre‐Olivier, Zysman, Maeva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346176/ https://www.ncbi.nlm.nih.gov/pubmed/35715960 http://dx.doi.org/10.1111/1759-7714.14464

Ejemplares similares

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
por: Patel, Shetal, et al.
Publicado: (2021)

A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer
por: Faubry, Clara, et al.
Publicado: (2022)

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
por: Hanvesakul, Raj, et al.
Publicado: (2023)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Pulmonary rehabilitation after severe exacerbation of COPD: a nationwide population study
por: Guecamburu, Marina, et al.
Publicado: (2023)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study
por: Heraudet, Luc, et al.
Publicado: (2022)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
por: Povo-Retana, Adrián, et al.
Publicado: (2020)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Lurbinectedin improves macular edema in a case of central retinal vein occlusion()
por: Simona, Filippo, et al.
Publicado: (2022)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin
por: Matsui, Shinji, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
por: Dusselier, Matthieu, et al.
Publicado: (2019)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
por: Fudio, Salvador, et al.
Publicado: (2020)

Muscarinic receptor M3 activation promotes fibrocytes contraction
por: Henrot, Pauline, et al.
Publicado: (2022)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
por: Costanzo, Federico, et al.
Publicado: (2022)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
por: Fudio, Salvador, et al.
Publicado: (2023)

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
por: Lima, Michelle, et al.
Publicado: (2016)

Are Cox-2 drugs the second line option in indomethacin responsive headaches?
por: Porta-Etessam, Jesús, et al.
Publicado: (2010)

Options for the second Bunch Compressor Chicane of the CLIC Main Beam Line
por: Stulle, F, et al.
Publicado: (2006)

Women's COPD
por: Zysman, Maéva, et al.
Publicado: (2022)

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
por: Kristeleit, Rebecca, et al.
Publicado: (2021)

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)

Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021)

Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
por: Slawek, Deepika, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u9ad6huikbelalrv6ob3ins7st